Partnering & Outsourcing Editorial

  1. 3 Strategies For A Successful Journey Toward Cell And Gene Therapy Commercialization 5/13/2025

    CTMC's Amy Hay provides 3 recommendations for teams developing cell and gene therapies, from clinical research through commercialization.

  2. The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials 5/12/2025

    Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.

  3. When To Outsource — And How To Pick The Perfect Clinical Trial Partners 5/9/2025

    EMED Technologies Director of Clinical Affairs Alex Nikanorov shares the company’s approach to deciding which clinical research functions to outsource and finding vendor partners that align with the company’s goals.

  4. What The Heck Are Financial Accruals? A Guide To Understanding The Mysterious Finance Brain 5/2/2025

    Clinical finance consultant Chris Chan helps clinical professionals understand financial accruals concepts and interpret requests from finance colleagues.

  5. How AI Redefines The Functional Service Provider Opportunity In Medical Affairs 4/7/2025

    Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

  6. Multiple Partnerships Help Drive Precision Medicine Trial For Parkinson's 3/31/2025

    Neuron23 CMO Sam Jackson, MD, explains the company’s desire to set a new standard in precision medicine for neurology, backed by well-aligned partnerships and fit-for-purpose digital biomarker solutions. 

  7. How PDS Biotech Approached FDA Meetings For Its Phase 3 Cancer Trial 2/11/2025

    PDS Biotech CMO Kirk Shepard reveals his team’s interactions with the FDA as it sought to begin its Phase 3 trial for the treatment of HPV-positive recurrent and/or metastatic head and neck squamous cell carcinoma.

  8. Biopharma R&D Faces Productivity And Attrition Challenges In 2025 1/29/2025

    Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly evolving industry dynamics, presents a productivity and attrition challenge for the industry.

  9. Tech Vendors Are Today's Don Quixotes 1/28/2025

    Don Quixote is known for tilting at windmills, believing them to be enemies. Today, it seems, emerging tech solution developers are embodying the spirit of the quixotic knight centuries later.

  10. Should You Choose An FSP Model? It Depends… 1/10/2025

    Small biotechs are often drawn to an FSP model because they believe it’s a less expensive option as compared to an FSO. But that’s not always the case, says Réne Stephens of Danforth Advisors, who gives some examples of what to consider before making your choice of outsourcing solution.